Improved survival among HIV-infected individuals following initiation of antiretroviral therapy

JAMA

Volumn 279, Issue 6, 1998, Pages 450-454

  Hogg, Robert S ^a,b   Heath, Katherine V ^a   Yip, Benita ^a   Craib, Kevin J P ^a   O'Shaughnessy, Michael V ^a,c,d   Schechter, Martin T ^a,b,d,e   Montaner, Julio S G ^a,b,c,d  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Canadian HIV Trials Network   (Canada)

^e BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; RETROVIRUS; SEROCONVERSION; SURVIVAL;

EID: 0032507027     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.6.450     Document Type: Article

References (33)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-191.
2. Graham NM, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992; 326:1037-1042.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
4. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992;327:581-587.
5. Hammer S, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
6. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
7. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: ACTG089. J Infect Dis. 1995;171(suppl2):5123-5130.
8. 3: results of a double-blind, placebo-controlled study. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 196.
9. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
10. Ridhy T, Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem. 1995;270:29621-29623.
11. Collier CA, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus disease. N Engl J Med. 1996;34:1011-1017.
12. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
13. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of 2 nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337: 725-733.
14. Mathez D, De Truchis P, Gorin I, et al. Ritonavir, AZT, DDC, as a triple combination in AIDS patients. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 285.
15. Cameron DW, Heath-Chiozzi M, Kravick S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: an update. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.411.
16. Vella S. Clinical experience with saquinavir. AIDS. 1996;9:21-25.
17. + cell counts 200-600 μL. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.294.
18. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194-1199.
19. + lymphocyte count relative to treatment and progression to AIDS. N Engl J Med. 1996;334:425-431.
20. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantification of HIV-RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995; 122:573-579.
21. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;72:1167-1170.
22. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendation of an international panel. JAMA. 1996;276:146-154.
23. Therapeutic Guidelines far the Treatment of HIV/AIDS and Related Conditions. Vancouver, British Columbia: Centre for Excellence in HIV/ AIDS; 1995.
24. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
25. Montaner JSG, Hogg RS, Yip B, Gataric N, Schechter MT, O'Shaughnessy MV. Increased zidovudine prescribing associated with lamivudine availability. JAMA. 1996;275:598.
26. World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemol Rec. 1990;65:221-228.
27. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
28. Neave HR, Worthington PL. Distribution-Free Tests. London, England: Routledge; 1998.
29. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-202.
30. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovidine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349:1413-1421.
31. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from tlie AIDS literature. Ann Intern Med. 1996;124:999-1005.
32. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol. 1987;126:14-24.
33. Graham NH, Hoover DR, Park LP, et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med. 1996;124: 1031-1038.